The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2019 | Afatinib for advanced EGFRm-positive NSCLC
Antonio Passaro
• 7 May 2019
Antonio Passaro, MD, PhD, of European Institute of Oncology IRCCS, Milan, Italy, presents interim data from a phase IIIB trial, comparing the outcomes of afatinib in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) patients with or without prior chemotherapy treatment. This video was recorded at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.
